NPHP

NPHP
Name	NPHP
Specialty	Nephrology
Causes	Genetic mutations
Diagnosis	Genetic testing
Treatment	Supportive care; transplantation

NPHP

Nephronophthisis (abbreviated as NPHP) is an autosomal recessive cystic kidney disorder characterized by progressive tubulointerstitial fibrosis leading to end-stage renal disease in childhood or adolescence. It is caused by mutations in a group of genes encoding proteins localized to the primary cilium, basal body, or centrosome, and it is associated with extrarenal manifestations affecting the retina, liver, skeleton, and central nervous system. Clinical recognition, genetic confirmation, and multidisciplinary management are critical to slow complications and to plan renal replacement therapy.

Overview

NPHP is a monogenic ciliopathy affecting renal tubular architecture with corticomedullary cysts and concentrating defects. The condition was first described in pediatric nephrology cohorts and has been linked to a broad spectrum of phenotypes ranging from isolated juvenile kidney failure to syndromic forms that overlap with Senior-Løken syndrome, Joubert syndrome, Meckel syndrome, and Bardet-Biedl syndrome. Pathogenic variants in multiple loci produce overlapping manifestations, reflecting shared molecular pathways involving the primary cilium and centrosomal complexes found in renal epithelial cells.

Genetics and Molecular Pathogenesis

NPHP results from pathogenic variants in at least two dozen genes, including canonical loci such as NPHP1 (homozygous deletion), GLIS2, INVS, NPHP3, CEP290, NEK8, TMEM67, IQCB1, CC2D2A, and TTC21B. These genes encode nephrocystins, tethering proteins, and ciliary transition zone components that interact with IFT88, IFT20, BBS1, ARL13B, OFD1, and RPGRIP1L in ciliary trafficking and signaling. Disruption of ciliary signaling perturbs pathways such as Wnt signaling, Hedgehog signaling, and planar cell polarity, leading to altered tubular morphogenesis, defective cell polarity, apoptosis, and fibrosis mediated by profibrotic mediators including TGF-β1. Modifier genes and oligogenic inheritance involving loci like THM1 or ANKS6 can modulate age at onset and extrarenal involvement. Genotype–phenotype correlations exist: for example, truncating variants in CEP290 are strongly associated with retinal dystrophy and early renal decline, while deletions of NPHP1 often present with isolated kidney disease.

Clinical Manifestations

Renal features include polyuria, polydipsia, nocturia, impaired urinary concentrating ability, and progressive renal insufficiency culminating in end-stage renal disease typically in the first two decades. Urinalysis often shows bland sediment and low-grade proteinuria. Imaging reveals small to normal-sized kidneys with corticomedullary cysts on ultrasound or magnetic resonance imaging. Extrarenal manifestations occur in syndromic forms: retinal degeneration in Senior-Løken syndrome causing night blindness and visual field constriction; cerebellar vermis hypoplasia with the "molar tooth sign" in Joubert syndrome producing ataxia and hypotonia; congenital hepatic fibrosis and portal hypertension in Meckel syndrome or related presentations; polydactyly, obesity, and hypogonadism in features overlapping Bardet-Biedl syndrome.

Diagnosis and Differential Diagnosis

Diagnosis relies on clinical suspicion in pediatric patients with bland urinary sediment, concentrating defects, and family history, supported by radiologic detection of corticomedullary cysts and growth failure. Definitive diagnosis uses targeted gene panels, whole-exome sequencing, or deletion analysis for loci like NPHP1. Differential diagnoses include autosomal dominant polycystic kidney disease (PKD1, PKD2), medullary cystic kidney disease (now often termed autosomal dominant tubulointerstitial kidney disease involving UMOD or MUC1), nephrocalcinosis from metabolic disorders such as primary hyperoxaluria (genes AGXT, GRHPR), and developmental syndromes like congenital anomalies of the kidney and urinary tract (CAKUT) involving HNF1B. Distinguishing features include inheritance pattern, age at onset, imaging pattern, and genetic testing.

Management and Treatment

There is no curative therapy to halt progression; management focuses on slowing complications, treating renal anemia, managing electrolyte abnormalities, and preparing for renal replacement therapy. Salt and water balance are maintained with dietary counseling and desmopressin is generally ineffective due to tubular defect. Management includes surveillance for extrarenal disease—ophthalmology for retinal dystrophy, hepatology for portal hypertension, and neurology for cerebellar dysfunction—with interventions such as retinal prosthesis referrals or portal hypertension management when indicated. End-stage renal disease is treated with dialysis modalities and renal transplantation, which generally has favorable outcomes; genetic counseling and family screening guide preimplantation or prenatal options. Emerging molecular therapies target ciliary signaling modulators and fibrosis pathways.

Prognosis and Epidemiology

Prognosis depends on genotype, age at onset, and presence of syndromic features; median age at end-stage renal disease varies by gene, from early childhood in severe syndromic forms to adolescence in typical juvenile presentations. Prevalence estimates vary geographically but NPHP is a leading genetic cause of pediatric end-stage renal disease in many cohorts. Carrier frequencies reflect founder mutations in populations studied, and consanguinity increases incidence. Long-term outcomes post-transplant are favorable regarding renal graft survival, though extrarenal manifestations require ongoing care.

Research Directions and Experimental Models

Research focuses on dissecting ciliary proteomes, modifier gene interactions, and signaling cascades using cellular models, patient-derived induced pluripotent stem cells, and animal models such as zebrafish, mouse knockouts (e.g., Cep290-null mouse), and medaka. High-throughput screens target modulators of ciliogenesis, autophagy, and fibrosis; gene-replacement strategies, antisense oligonucleotides, and small-molecule modulators of Hedgehog and TGF-β pathways are under investigation. Collaborative consortia and registries accelerate genotype–phenotype mapping and trials of precision therapies.

Category:Genetic kidney diseases